Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic …
RK Ramanathan, SL McDonough, PA Philip… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan
(HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The …
(HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The …
Optimizing first-line chemotherapy in metastatic pancreatic cancer: efficacy of FOLFIRINOX versus nab-paclitaxel plus gemcitabine
F Di Costanzo, F Di Costanzo, L Antonuzzo, E Mazza… - Cancers, 2023 - mdpi.com
Simple Summary Metastatic PC often represents a complex decision-making moment for
oncologists, particularly due to the general conditions of the patients, age, and the potential …
oncologists, particularly due to the general conditions of the patients, age, and the potential …
Advanced pancreatic ductal adenocarcinoma: moving forward
C Franck, C Müller, R Rosania, RS Croner, M Pech… - Cancers, 2020 - mdpi.com
Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30
years and is likely to further increase, making PDAC a leading cause of cancer-related death …
years and is likely to further increase, making PDAC a leading cause of cancer-related death …
[HTML][HTML] A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
M Ozaka, K Nakachi, S Kobayashi, A Ohba… - European Journal of …, 2023 - Elsevier
Aim We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and
oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally …
oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally …
Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy
M Sugimori, K Sugimori, H Tsuchiya, Y Suzuki… - Cancer …, 2020 - Wiley Online Library
According to cancer genome sequences, more than 90% of cases of pancreatic ductal
adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables …
adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables …
Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified …
Y Ushida, Y Inoue, A Oba, T Mie, H Ito, Y Ono… - Annals of Surgical …, 2022 - Springer
Background The prognosis of initially unresectable pancreatic cancer (UR-PC) has
improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel …
improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel …
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
M Sawada, A Kasuga, T Mie, T Furukawa, T Taniguchi… - BMC cancer, 2020 - Springer
Background There is no established second-line treatment after failure of gemcitabine plus
nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this …
nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this …
Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: intention‐to‐treat analysis compared with upfront surgery
Y Inoue, A Saiura, A Oba, Y Ono, Y Mise… - Journal of Hepato …, 2021 - Wiley Online Library
Abstract Background/Purpose We evaluated efficacy of neoadjuvant therapy with
gemcitabine and nab‐paclitaxel (GNP‐NAT) in borderline resectable pancreatic cancer (BR …
gemcitabine and nab‐paclitaxel (GNP‐NAT) in borderline resectable pancreatic cancer (BR …
Selection bias due to delayed comprehensive genomic profiling in Japan
T Tamura, M Ikegami, Y Kanemasa, M Yomota… - Cancer …, 2023 - Wiley Online Library
Patients with advanced cancer undergo comprehensive genomic profiling in Japan only
after treatment options have been exhausted. Patients with a very poor prognosis were not …
after treatment options have been exhausted. Patients with a very poor prognosis were not …
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative …
YY Su, YF Chiu, CP Li, SH Yang, J Lin, SJ Lin… - British Journal of …, 2022 - nature.com
Background The objective of this study was to evaluate the efficacy and safety of induction
chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) …
chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) …